
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences Inc. presents a positive outlook due to the differentiated profile of cytisinicline, which demonstrates improved safety and has the potential to disrupt the smoking cessation market. The statistically significant abstinence results from the pilot P2 ORCA-V1 trial, with an odds ratio of 2.6, indicate broad potential clinical utilization among the 11 million U.S. adults and 2 million middle/high school e-cigarette users interested in quitting. Moreover, management's collaboration with the FDA on a long-term study and the planned initiation of the ORCA OL trial in Q2 2024 position the company favorably for future growth and approval of cytisinicline for vaping cessation.
Bears say
Achieve Life Sciences faces several downside risks that contribute to a negative outlook on its stock, including the potential failure of the ORCA-3 Phase 3 trial to meet endpoints, slow enrollment in ORCA trials, and limited market penetration of cytisinicline due to the generic availability of Chantix. The company's recent first-quarter 2024 report indicated an earnings per share (EPS) of ($0.26), which fell short of both its estimates and the broader market consensus of ($0.24), highlighting ongoing financial challenges. Despite the extensive clinical evidence supporting cytisinicline, its lack of launch in major markets after over 20 years of being on the market poses significant concerns regarding its commercial viability.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares